Directed To Deliver

Voyager is advancing early-stage programs powered by proprietary, next-generation AAV capsids to deliver innovative gene therapies using various payloads. The pipeline supports the Company’s strategic vision for developing best-in-class treatments by focusing on validated targets, following efficient pathways to preclinical and clinical proof of concept, and seeking opportunities to provide meaningful therapeutic benefit to patients in areas of significant unmet need.

Indication (Mechanism)


Early Research

Late Research


Alzheimer’s disease
Anti-tau Antibody (VY-TAU01)
Late Research

Voyager is developing novel and complementary approaches to disrupt the progression of tau pathology to address tauopathies including Alzheimer’s disease. We believe our passive-immunity anti-tau antibodies are highly differentiated from competitive approaches by offering improved targeting of specific regions of the tau protein that could offer an improved clinical profile compared to first generation approaches.

Alzheimer’s Early Research
•Tau gene silencing for Alzheimer’s
•Vectorized anti-Aβ antibody for Alzheimer’s
Early Research
SOD1 Gene Therapy (Gene Silencing)
Late Research

Superoxide dismutase 1 (SOD1) mutations cause toxic gain of function in forms of familial amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with minimally effective treatments. Voyager’s SOD1 knockdown program aims to address ALS caused by SOD1 mutations by combining a highly potent siRNA construct with a CNS-tropic, BBB penetrant capsid identified from Voyager’s TRACER platform, allowing for intravenous AAV dosing to enable broad CNS knockdown of SOD1 and slow of the decline of functional ability.

Other Early Research
•Allele-specific mHTT + MSH3 gene silencing for HD
•Vectorized HER2 antibody for brain metastases
Early Research
Parkinson’s / Others
GBA1 Gene Therapy (Gene Replacement)
Neurocrine Collaboration (VYGR has 50% cost/profit split option)
Late Research
Friedreich’s Ataxia
FXN Gene Therapy (Gene Replacement)
Neurocrine Collaboration (VYGR has 40% cost/profit split option)
Late Research
Undisclosed Diseases
Five Gene Therapy Programs
Neurocrine Collaboration
Rare Neurological Disease
Gene Therapy
Alexion, AstraZeneca Rare Disease License
CNS Diseases
Two Gene Therapy Programs
Novartis License
Prion Disease
Gene Therapy
Sangamo License

Patient Resources

Here we have gathered resources for patients and caregivers looking to better understand the diseases we seek to treat. If you are a patient or caregiver, please feel free to contact Voyager with questions: info@voyagertherapeutics.com

Alzheimer’s Disease

Amyotrophic Lateral Sclerosis

Huntington’s Disease

Parkinson’s Disease

Additional Resources

Contact Us

Voyager Therapeutics
75 Hayden Ave | Lexington, MA 02421